Laboratory Studies for Subacute Stroke
All patients with subacute stroke should undergo a core panel of laboratory tests including complete blood count with platelets, serum electrolytes, renal function tests, blood glucose, HbA1c, fasting or non-fasting lipid profile, prothrombin time/INR, activated partial thromboplastin time, and cardiac biomarkers (troponin). 1, 2, 3
Core Laboratory Panel (All Patients)
The following tests should be completed or underway within 48 hours of stroke onset 4:
Hematologic Studies
- Complete blood count with platelet count - identifies anemia, polycythemia, thrombocytopenia, or thrombocytosis that may contribute to stroke risk or influence treatment decisions 1, 2
- Prothrombin time/INR and activated partial thromboplastin time - essential for detecting coagulopathies and guiding anticoagulation decisions 1, 3
Metabolic Studies
- Blood glucose - hypoglycemia can mimic stroke symptoms, while hyperglycemia is associated with worse outcomes 1, 2
- HbA1c - screens for diabetes and assesses glycemic control 5, 6, 4
- Serum electrolytes - identifies metabolic derangements that may contribute to neurological symptoms 1, 3
- Renal function tests (creatinine, eGFR) - important for medication dosing and identifying renal disease as a vascular risk factor 1, 5
Lipid Studies
- Fasting or non-fasting lipid profile - guides statin therapy decisions for secondary prevention 4, 5
Cardiac Studies
- Cardiac biomarkers (troponin preferred) - acute myocardial infarction can precipitate stroke or occur concurrently; troponin is more sensitive and specific than creatine kinase 1, 2, 3
Selected Additional Tests (Based on Clinical Suspicion)
When Specific Conditions Are Suspected
- Hepatic function tests - if liver disease suspected or patient on medications requiring hepatic monitoring 1, 3
- Toxicology screen and blood alcohol level - when substance use is uncertain or suggested by examination 1, 7, 3
- Pregnancy test - in women of childbearing age 1, 3
For Cryptogenic Stroke Evaluation
When stroke etiology remains unclear after initial workup, consider 4:
- Tests for hypercoagulable states - as clinically indicated
- Markers of systemic inflammation
- Infectious disease screening (HIV, syphilis) - when CNS vasculitis suspected
- Drug screening - for cocaine, amphetamines if relevant
Important Caveats
Timing Considerations
While these tests are essential, thrombolytic therapy should not be delayed awaiting results unless 1, 2:
- Clinical suspicion of bleeding abnormality or thrombocytopenia exists
- Patient has received heparin, warfarin, or other anticoagulants
- Anticoagulant use is uncertain
Tests NOT Routinely Recommended
- Chest radiography - only altered clinical management in 3.8% of cases; perform only if lung disease clinically suspected 1, 2, 3
- Lumbar puncture - only if subarachnoid hemorrhage suspected and CT negative for blood 1, 3
- Arterial blood gas - only if hypoxia suspected 1, 3
Integration with Other Diagnostics
Laboratory studies complement but do not replace:
- 12-lead ECG - mandatory for all patients to screen for atrial fibrillation and cardiac ischemia 1, 4
- Brain imaging (CT or MRI) - confirms diagnosis 4
- Vascular imaging - identifies large vessel disease requiring intervention 5, 6
- Prolonged cardiac monitoring (≥24 hours, ideally ≥2 weeks) - detects paroxysmal atrial fibrillation in cryptogenic stroke 5, 6, 4
The laboratory evaluation serves multiple critical functions: ruling out stroke mimics (hypoglycemia), identifying conditions requiring urgent treatment (cardiac ischemia), guiding acute therapy decisions (coagulation studies), and informing secondary prevention strategies (lipids, HbA1c). This systematic approach ensures comprehensive evaluation while avoiding unnecessary delays in time-sensitive interventions.